The factor XIII-A Val34Leu polymorphism decreases whole blood clot mass at high fibrinogen concentrations.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Factor XIII (FXIII) promotes fibrin crosslinking and red blood cell (RBC) retention in clots. The FXIII-A polymorphism, Val34Leu, is associated with protection against venous thrombosis. This effect is hypothesized to result from fibrinogen concentration-dependent changes in fibrin structure. Effects of the FXIII-A Val34Leu polymorphism in whole blood clots have not been investigated.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J Thromb Haemost

Title: Journal of thrombosis and haemostasis : JTH

Publisher: Wiley

ISSN (Electronic): 1538-7836

ISSN (Print): 1538-7836

Publication date (Electronic): April 2020

Volume: 18

Issue: 4

Affiliations

[1 ] Department of Pathology and Laboratory Medicine and UNC Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

[2 ] Division of Clinical Laboratory Science, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

[3 ] MTA-DE Cerebrovascular and Neurodegenerative Research Group, University of Debrecen, Debrecen, Hungary.

Article

Mid ID: NIHMS1690808

DOI: 10.1111/jth.14744

PMC ID: 8059250

PubMed ID: 31989767

SO-VID: e714c31c-d9fe-41b0-9bc5-5ef5b6ae4ab5

History

Keywords: erythrocyte,factor XIII,fibrinogen,thrombosis,transglutaminase

Data availability:

Keywords: erythrocyte, factor XIII, fibrinogen, thrombosis, transglutaminase

Comments

Comment on this article

scite_

Cited by 2

See all cited by